Limits...
Modelling vaccination schedules for a cancer immunoprevention vaccine.

Motta S, Castiglione F, Lollini P, Pappalardo F - Immunome Res (2005)

Bottom Line: This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma.In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma.We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Mathematics and Computer Science, University of Catania, Catania, Italy. motta@dmi.unict.it

ABSTRACT
We present a systematic approach to search for an effective vaccination schedule using mathematical computerized models. Our study is based on our previous model that simulates the cancer vs immune system competition activated by tumor vaccine. This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma. In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma. The full protection was conferred using chronic (prophylactic) vaccination protocol while therapeutic vaccination was less efficient. In the present paper we use the computer simulations to systematically search for a vaccination schedule which prevents solid tumor formation. The strategy we used for defining a successful vaccination schedule is to control the number of cancer cells with vaccination cycles. We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

No MeSH data available.


Related in: MedlinePlus

Tumor-free survival curves of virtual mice receiving the Triplex vaccine according to different protocols. Each arrow at the bottom of the graph represents one cycle of vaccination. The sequence of neoplastic progression in untreated mice is outlined under the x axis; CIS, carcinoma in situ.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC1287065&req=5

Figure 4: Tumor-free survival curves of virtual mice receiving the Triplex vaccine according to different protocols. Each arrow at the bottom of the graph represents one cycle of vaccination. The sequence of neoplastic progression in untreated mice is outlined under the x axis; CIS, carcinoma in situ.

Mentions: The computational time begins when the mouse is six weeks old (the observed time of atypical hyperplasia) and proceeds up to the formation of a solid tumor or up to 2 years. For each protocol we treat all mice in the sample and we measure the time in which the solid tumor is formed. The percentage of tumor free mice as function of age is shown in Figure 4 for sample S2 (the same result for sample S1 has been shown in [16]). Comparison with Figure 1 shows excellent agreement with in vivo experiments.


Modelling vaccination schedules for a cancer immunoprevention vaccine.

Motta S, Castiglione F, Lollini P, Pappalardo F - Immunome Res (2005)

Tumor-free survival curves of virtual mice receiving the Triplex vaccine according to different protocols. Each arrow at the bottom of the graph represents one cycle of vaccination. The sequence of neoplastic progression in untreated mice is outlined under the x axis; CIS, carcinoma in situ.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC1287065&req=5

Figure 4: Tumor-free survival curves of virtual mice receiving the Triplex vaccine according to different protocols. Each arrow at the bottom of the graph represents one cycle of vaccination. The sequence of neoplastic progression in untreated mice is outlined under the x axis; CIS, carcinoma in situ.
Mentions: The computational time begins when the mouse is six weeks old (the observed time of atypical hyperplasia) and proceeds up to the formation of a solid tumor or up to 2 years. For each protocol we treat all mice in the sample and we measure the time in which the solid tumor is formed. The percentage of tumor free mice as function of age is shown in Figure 4 for sample S2 (the same result for sample S1 has been shown in [16]). Comparison with Figure 1 shows excellent agreement with in vivo experiments.

Bottom Line: This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma.In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma.We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Mathematics and Computer Science, University of Catania, Catania, Italy. motta@dmi.unict.it

ABSTRACT
We present a systematic approach to search for an effective vaccination schedule using mathematical computerized models. Our study is based on our previous model that simulates the cancer vs immune system competition activated by tumor vaccine. This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma. In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma. The full protection was conferred using chronic (prophylactic) vaccination protocol while therapeutic vaccination was less efficient. In the present paper we use the computer simulations to systematically search for a vaccination schedule which prevents solid tumor formation. The strategy we used for defining a successful vaccination schedule is to control the number of cancer cells with vaccination cycles. We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

No MeSH data available.


Related in: MedlinePlus